Summary

Brugada Syndrome Market – Scope of Report
TMR’s report on the global brugada syndrome market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global brugada syndrome market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global brugada syndrome market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the brugada syndrome market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global brugada syndrome market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global brugada syndrome market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global brugada syndrome market.

The report delves into the competitive landscape of the global brugada syndrome market. Key players operating in the global brugada syndrome market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global brugada syndrome market profiled in this report.

Key Questions Answered in Global brugada syndrome Market Report
• What is the sales/revenue generated by brugada syndrome across all regions during the forecast period?
• What are the opportunities in the global brugada syndrome market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Brugada Syndrome Market – Research Objectives and Research Approach
The comprehensive report on the global brugada syndrome market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global brugada syndrome market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global brugada syndrome market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Brugada Syndrome Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Brugada Syndrome Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Brugada Syndrome Market Analysis and Forecast, by Diagnosis Methods
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Diagnosis Methods, 2020-2034
6.3.1. Electrocardiogram (ECG)
6.3.2. Echocardiogram
6.3.3. Electrophysiological (EP) Testing and Mapping
6.3.4. Others (Genetic Testing, etc.)
6.4. Market Attractiveness, by Diagnosis Methods
7. Global Brugada Syndrome Market Analysis and Forecast, by Treatment Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment Type, 2020-2034
7.3.1. Surgical Methods
7.3.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
7.3.1.2. Radiofrequency Catheter Ablation
7.3.2. Drug Therapy
7.3.2.1. Antiarrhythmic Drugs
7.3.2.2. Psychotropic Drugs
7.3.2.3. Analgesic Drugs
7.3.2.4. Others (beta-blockers, etc.)
7.4. Market Attractiveness, by Treatment Type
8. Global Brugada Syndrome Market Analysis and Forecast, by Indication Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication Type, 2020-2034
8.3.1. Brugada Type 1
8.3.2. Brugada Type 2
8.4. Market Attractiveness, by Indication Type
9. Global Brugada Syndrome Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals & Clinics
9.3.2. Surgical Centers
9.3.3. Diagnostic Centers
9.3.4. Others (Beta-blockers, etc.)
9.4. Market Attractiveness, by End-user
10. Global Brugada Syndrome Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Brugada Syndrome Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Diagnosis Methods, 2020-2034
11.2.1. Electrocardiogram (ECG)
11.2.2. Echocardiogram
11.2.3. Electrophysiological (EP) Testing and Mapping
11.2.4. Others (Genetic Testing, etc.)
11.3. Market Attractiveness, by Diagnosis Methods
11.4. Market Value Forecast, by Treatment Type, 2020-2034
11.4.1. Surgical Methods
11.4.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
11.4.1.2. Radiofrequency Catheter Ablation
11.4.2. Drug Therapy
11.4.2.1. Antiarrhythmic Drugs
11.4.2.2. Psychotropic Drugs
11.4.2.3. Analgesic Drugs
11.4.2.4. Others (beta-blockers, etc.)
11.5. Market Attractiveness, by Treatment Type
11.6. Market Value Forecast, by Indication Type, 2020-2034
11.6.1. Brugada Type 1
11.6.2. Brugada Type 2
11.7. Market Attractiveness, by Indication Type
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals & Clinics
11.8.2. Surgical Centers
11.8.3. Diagnostic Centers
11.8.4. Others (Beta-blockers, etc.)
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Diagnosis Methods
11.11.2. By Treatment Type
11.11.3. By Indication Type
11.11.4. By End-user
11.11.5. By Country
12. Europe Brugada Syndrome Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Diagnosis Methods, 2020-2034
12.2.1. Electrocardiogram (ECG)
12.2.2. Echocardiogram
12.2.3. Electrophysiological (EP) Testing and Mapping
12.2.4. Others (Genetic Testing, etc.)
12.3. Market Attractiveness, by Diagnosis Methods
12.4. Market Value Forecast, by Treatment Type, 2020-2034
12.4.1. Surgical Methods
12.4.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
12.4.1.2. Radiofrequency Catheter Ablation
12.4.2. Drug Therapy
12.4.2.1. Antiarrhythmic Drugs
12.4.2.2. Psychotropic Drugs
12.4.2.3. Analgesic Drugs
12.4.2.4. Others (beta-blockers, etc.)
12.5. Market Attractiveness, by Treatment Type
12.6. Market Value Forecast, by Indication Type, 2020-2034
12.6.1. Brugada Type 1
12.6.2. Brugada Type 2
12.7. Market Attractiveness, by Indication Type
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals & Clinics
12.8.2. Surgical Centers
12.8.3. Diagnostic Centers
12.8.4. Others (Beta-blockers, etc.)
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Diagnosis Methods
12.11.2. By Treatment Type
12.11.3. By Indication Type
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Brugada Syndrome Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Diagnosis Methods, 2020-2034
13.2.1. Electrocardiogram (ECG)
13.2.2. Echocardiogram
13.2.3. Electrophysiological (EP) Testing and Mapping
13.2.4. Others (Genetic Testing, etc.)
13.3. Market Attractiveness, by Diagnosis Methods
13.4. Market Value Forecast, by Treatment Type, 2020-2034
13.4.1. Surgical Methods
13.4.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
13.4.1.2. Radiofrequency Catheter Ablation
13.4.2. Drug Therapy
13.4.2.1. Antiarrhythmic Drugs
13.4.2.2. Psychotropic Drugs
13.4.2.3. Analgesic Drugs
13.4.2.4. Others (beta-blockers, etc.)
13.5. Market Attractiveness, by Treatment Type
13.6. Market Attractiveness, by Treatment Type
13.7. Market Value Forecast, by Indication Type, 2020-2034
13.7.1. Brugada Type 1
13.7.2. Brugada Type 2
13.8. Market Attractiveness, by Indication Type
13.9. Market Value Forecast, by End-user, 2020-2034
13.9.1. Hospitals & Clinics
13.9.2. Surgical Centers
13.9.3. Diagnostic Centers
13.9.4. Others (Beta-blockers, etc.)
13.10. Market Attractiveness, by End-user
13.11. Market Value Forecast, by Country/Sub-region, 2020-2034
13.11.1. China
13.11.2. Japan
13.11.3. India
13.11.4. Australia & New Zealand
13.11.5. Rest of Asia Pacific
13.12. Market Attractiveness Analysis
13.12.1. By Diagnosis Methods
13.12.2. By Treatment Type
13.12.3. By Indication Type
13.12.4. By End-user
13.12.5. By Country/Sub-region
14. Latin America Brugada Syndrome Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Diagnosis Methods, 2020-2034
14.2.1. Electrocardiogram (ECG)
14.2.2. Echocardiogram
14.2.3. Electrophysiological (EP) Testing and Mapping
14.2.4. Others (Genetic Testing, etc.)
14.3. Market Attractiveness, by Diagnosis Methods
14.4. Market Value Forecast, by Treatment Type, 2020-2034
14.4.1. Surgical Methods
14.4.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
14.4.1.2. Radiofrequency Catheter Ablation
14.4.2. Drug Therapy
14.4.2.1. Antiarrhythmic Drugs
14.4.2.2. Psychotropic Drugs
14.4.2.3. Analgesic Drugs
14.4.2.4. Others (beta-blockers, etc.)
14.5. Market Attractiveness, by Treatment Type
14.6. Market Value Forecast, by Indication Type, 2020-2034
14.6.1. Brugada Type 1
14.6.2. Brugada Type 2
14.7. Market Attractiveness, by Indication Type
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals & Clinics
14.8.2. Surgical Centers
14.8.3. Diagnostic Centers
14.8.4. Others (Beta-blockers, etc.)
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Diagnosis Methods
14.11.2. By Treatment Type
14.11.3. By Indication Type
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Brugada Syndrome Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Diagnosis Methods, 2020-2034
15.2.1. Electrocardiogram (ECG)
15.2.2. Echocardiogram
15.2.3. Electrophysiological (EP) Testing and Mapping
15.2.4. Others (Genetic Testing, etc.)
15.3. Market Attractiveness, by Diagnosis Methods
15.4. Market Value Forecast, by Treatment Type, 2020-2034
15.4.1. Surgical Methods
15.4.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
15.4.1.2. Radiofrequency Catheter Ablation
15.4.2. Drug Therapy
15.4.2.1. Antiarrhythmic Drugs
15.4.2.2. Psychotropic Drugs
15.4.2.3. Analgesic Drugs
15.4.2.4. Others (beta-blockers, etc.)
15.5. Market Attractiveness, by Treatment Type
15.6. Market Value Forecast, by Indication Type, 2020-2034
15.6.1. Brugada Type 1
15.6.2. Brugada Type 2
15.7. Market Attractiveness, by Indication Type
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals & Clinics
15.8.2. Surgical Centers
15.8.3. Diagnostic Centers
15.8.4. Others (Beta-blockers, etc.)
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Diagnosis Methods
15.11.2. By Treatment Type
15.11.3. By Indication Type
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. GeneDx, LLC
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. GE HealthCare
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. GSK plc
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Lilly India
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Boston Scientific Corporation
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Pfizer Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview